泛免疫炎症值在直肠癌患者高压氧联合新辅助放化疗序贯治疗后的预测价值  

Predictive significance of pan-immune inflammatory value in rectal cancer patients after sequential treatment of hyperbaric oxygen combined with neoadjuvant chemoradiotherapy

作　　者：王玉霞 苑小娟 王永凤[1] 段晓娜 申惠英 Wang Yuxia;Yuan Xiaojuan;Wang Yongfeng;Duan Xiaona;Shen Huiying(Affiliated Hospital of Hebei University of Engineering,Handan 056001,China;Handan Maternal and Child Health Care Hospital,Handan 056004,China)

机构地区：[1]河北工程大学附属医院,邯郸056001 [2]邯郸市妇幼保健院新生儿科,邯郸056004

出　　处：《中华航海医学与高气压医学杂志》2025年第3期249-253,共5页Chinese Journal of Nautical Medicine and Hyperbaric Medicine

基　　金：河北省医学科研计划资组项目(20242117)。

摘　　要：目的探讨泛免疫炎症值(PIV)在直肠癌患者高压氧联合新辅助放化疗序贯治疗后的预测价值。方法选取2021年1—12月河北工程大学附属医院肛肠科收治的88例直肠癌患者作为研究对象,均予以高压氧联合新辅助放化疗序贯治疗。比较治疗前后直肠癌患者PIV变化。根据治疗后直肠癌患者PIV数据绘制受试者工作特征(ROV)曲线,获得PIV最佳临界值为229.4,根据最佳临界值将患者分为高PIV组(PIV≥229.4,n=36)和低PIV组(PIV<229.4,n=52),分析PIV与患者临床病理资料的关系。跟踪记录治疗后2年内患者生存情况,比较高PIV组和低PIV组直肠癌患者生存期,并分析PIV对直肠癌患者的预后价值。结果治疗后直肠癌患者PIV明显低于治疗前[(216.47±8.52)vs.(467.58±12.39),t=156.658,P<0.001]。多因素COX回归分析结果显示,PIV与直肠癌患者肿瘤直径、TNM分期、淋巴结转移、脉管内瘤栓及血清癌胚抗原(CEA)、糖类抗原(CA)19-9、CA125水平具有相关性(均P<0.05)。随访截止至2023年10月30日,直肠癌高PIV组患者中位生存时间明显低于低PIV组[(14.26±3.58)个月vs.(17.24±3.69)个月,t=3.909,P=0.002]。结论高压氧联合新辅助放化疗序贯治疗后直肠癌患者PIV明显降低,PIV对评估直肠癌患者预后及放化疗效果具有重要参考价值。Objective To explore the predictive significance of pan-immune inflammation value(PIV)in rectal cancer patients after sequential treatment of hyperbaric oxygen combined with neoadjuvant chemoradiotherapy.Methods A total of 88 rectal cancer patients admitted to the Department of Proctology of Affiliated Hospital of Hebei University of Engineering from January to December 2021 were selected as the study subjects,who received sequential treatment of hyperbaric oxygen combined with neoadjuvant chemoradiotherapy.Changes in PIV before and after treatment in those patients were compared.Receiver operating characteristic(ROC)curves were plotted based on the PIV data of the patients after treatment,and the cut-off value of PIV was obtained as 229.4.Patients were divided into high PIV group(PIV≥229.4)and low PIV group(PIV<229.4)according to the cut-off value.The relationship between PIV and clinical pathological data was analyzed.The survival status of the patients within two years after treatment was followed up;the survival periods of rectal cancer patients in the high and low PIV groups were compared,and the significance of PIV for predicting prognosis of rectal cancer patients was analyzed.Results The PIV of rectal cancer patients after treatment was significantly lower than that before treatment[(216.47±8.52)vs.(467.58±12.39),t=156.658,P<0.001].The multivariate Cox regression analysis showed that PIV was correlated with tumor diameter,TNM staging,lymph node metastasis,intravascular tumor thrombus,and serum CEA,CA19-9,and CA125 levels in patients with rectal cancer(all P<0.05).As of October 30,2023,the median survival time of rectal cancer patients in the high PIV group was significantly lower than that in the low PIV group[(14.26±3.58)months vs.(17.24±3.69)months,t=3.909,P=0.002].Conclusion After sequential treatment of hyperbaric oxygen combined with neoadjuvant chemoradiotherapy,the PIV of patients with rectal cancer is significantly reduced.PIV has important reference significance in evaluating the prognosis

关 键 词：直肠癌 泛免疫炎症值 高压氧 放化疗序贯治疗 

分 类 号：R735.3[医药卫生—肿瘤]